AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Arcutis Biotherapeutics: Matsuda Masaru sells 1,800 shares at $13.78 per share.
ByAinvest
Thursday, May 29, 2025 8:31 pm ET1min read
Arcutis Biotherapeutics, Inc. (ARQT) has announced that Matsuda Masaru, a member of the company's board of directors, has sold 1,800 shares of the company's stock at a price of $13.78 per share on May 28, 2023.
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) has announced that Masaru Matsuda, a board member, sold 1,800 shares of the company's stock on May 28, 2023, at a price of $13.78 per share. This transaction, disclosed in a filing with the Securities & Exchange Commission, indicates a decrease in Matsuda's ownership in the company [1].The sale of 1,800 shares by Matsuda represents a 0.08% reduction in his total ownership, as he now holds 204,399 shares valued at approximately $3,106,864.80. This transaction follows a previous sale of 5,030 shares on May 2, 2023, at an average price of $15.20 per share [1].
Arcutis Biotherapeutics, Inc. focuses on developing and commercializing treatments for dermatological diseases, with its lead product candidate, ARQ-151, a topical roflumilast cream, completing Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis [1].
In recent quarters, the company has seen significant institutional investment. BNP Paribas Financial Markets bought 79,815 shares in the 4th quarter of 2022, valued at approximately $1,112,000. Additionally, several hedge funds have added to their stakes in the company [1].
Analysts have shown varying opinions on the stock. Mizuho raised their target price from $20.00 to $21.00 and gave the stock an "outperform" rating. Needham & Company, Jefferies Financial Group, HC Wainwright, and Goldman Sachs have also issued "buy" ratings with target prices ranging from $16.00 to $21.00. The stock currently has an average rating of "Moderate Buy" and an average target price of $18.80 [1].
Arcutis Biotherapeutics reported ($0.20) earnings per share for the quarter ending May 6, 2023, beating analysts' consensus estimates of ($0.21). The company's revenue for the quarter was $65.85 million, compared to analysts' expectations of $64.80 million [1].
The stock's price performance has been volatile, with a 52-week low of $6.99 and a 52-week high of $17.75. The stock has a market cap of $1.67 billion, a price-to-earnings ratio of -7.81, and a beta of 1.87 [1].
References:
[1] https://www.marketbeat.com/instant-alerts/filing-79815-shares-in-arcutis-biotherapeutics-inc-nasdaqarqt-acquired-by-bnp-paribas-financial-markets-2025-05-21/
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet